Screener
Arcutis Biotherapeutics, Inc. ARQT Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 91.1%+2.0pp | 90.9%+2.5pp | 90.2%0.0pp | 90%+0.4pp | 89.1%-3.2pp | |
| Efficiency | ||||||
| Asset turnover | 1.1×+0.4× | 1×+0.5× | 1×+0.4× | 0.8×+0.4× | 0.7×+0.3× | |
| Liquidity | ||||||
| Current ratio | 2.9×-0.3× | 2.7×-0.9× | 3.2×-1.0× | 3.5×+1.0× | 3.2×-5.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.5×-0.3× | 0.6×-0.2× | 0.6×-0.1× | 0.7×-0.6× | 0.8×-0.3× | |
| Per Share | ||||||
| Book value per share | $1.62+48.3% | $1.47+29.5% | $1.49+14.3% | $1.19-5.6% | $1.09-27.5% | |
| Valuation | ||||||
| Market capitalization | $3.32B+81.4% | $2.92B+57.5% | $3.56B+118% | $2.26B+108% | $1.71B+58.7% | |
| Price / sales | 7.2×+0.2× | 7×-1.7× | 9.5×+1.2× | 7.1×-0.7× | 6.5×-1.7× | |
| Price / book | 15.1×+1.9× | 15.4×+2.4× | 18.8×+8.4× | 14.3×+7.4× | 12.3×+6.5× |
FAQ
- What are Arcutis Biotherapeutics, Inc.'s profit margins?
- Arcutis Biotherapeutics, Inc. (ARQT) runs a 91.1% gross margin and a -12.0% operating margin, with a -13.9% net margin.
- Where do Arcutis Biotherapeutics, Inc.'s ratios come from?
- Every ratio is computed from Arcutis Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
